Patents Examined by Anne-Marie Falk
-
Patent number: 8476070Abstract: Well-defined, xeno-free culture media which comprise a TGF-beta isoform or the chimera formed between IL6 and the soluble IL6 receptor (IL6RIL6), which are capable of maintaining stem cells, and particularly, human embryonic stem cells, in an undifferentiated state are provided. Also provided are cell cultures comprising the culture media and the stem cells and methods of expanding and deriving embryonic stem cells in such well-defined, xeno-free culture media. In addition, the present invention provides methods of differentiating ESCs or EBs formed therefrom for the generation of lineage specific cells.Type: GrantFiled: August 29, 2006Date of Patent: July 2, 2013Assignee: Technion Research & Development Foundation LimitedInventors: Michal Amit, Joseph Itskovitz-Eldor
-
Patent number: 8445279Abstract: Facing no ethical obstacle and easily to be isolated, multipotent concretely mesenchymal stem cells (MSCs) are one of the most powerful tools in reconstructive medicine. Here the inventors introduced 3D multicelluar spheroids culture construction based on photolithography and micropatterning techniques to improve multipotent differentiation efficiency of MSCs to adult cells. This invention, the 3D spheroid cultured construction for MSCs, leads to great improve of the differentiation efficiency. This invention relates to a cultured cell construct comprising a support; at least one island on the support; a hydrophilic and cytophobic substance applied on the surface of said support so as to encircle the island; and a spheroid which is derived from MSCs, said spheroid being in contact with the island.Type: GrantFiled: October 21, 2008Date of Patent: May 21, 2013Assignee: Transparent Inc.Inventors: Wenjie Wang, Keiji Itaka, Shinsuke Ohba, Nobuhiro Nishiyama, Ung-il Chung, Yuichi Yamasaki, Kazunori Kataoka
-
Patent number: 8431767Abstract: Transgenic immunodeficient non-human animals according to embodiments of the present invention are described which include in their genome a nucleic acid encoding xenogeneic Stem Cell Factor operably linked to a promoter. Administration of xenogeneic hematopoetic stem cells to the inventive transgenic animals results in engraftment of the xenogeneic hematopoetic stem cells and xenogeneic leukocytes are produced in the animals, without conditioning such as without conditioning by irradiation and without conditioning by a radiomimetic agent.Type: GrantFiled: November 9, 2010Date of Patent: April 30, 2013Assignees: The Jackson Laboratory, University of Massachusetts Medical SchoolInventors: Leonard D. Shultz, Dale L. Greiner
-
Patent number: 8389250Abstract: A method of producing methionine, derivatives or precursors thereof comprising culturing a microorganism modified to enhance production of cysteine in a culture medium comprising a source of carbon and a source of sulfur and recovering methionine from the culture medium. A microorganism for fermentative production of methionine or its derivatives in which production of methionine or derivatives thereof, wherein the microorganism enhances production of cysteine.Type: GrantFiled: January 4, 2006Date of Patent: March 5, 2013Assignee: Metabolic ExplorerInventors: Rainer Figge, Fabien Lux, Céline Raynaud, Michel Chateau, Philippe Soucaille
-
Patent number: 8372643Abstract: There is provided a method of culturing a stem cell on extracellular matrix extracted from support cells and in a stem cell culture medium comprising medium conditioned by the support cells.Type: GrantFiled: December 5, 2008Date of Patent: February 12, 2013Assignee: Agency for Science, Technology and ResearchInventors: Jackie Y. Ying, Andrew Chwee Aun Wan, Karthikeyan Narayanan, Karl M. Schumacher
-
Patent number: 8367406Abstract: Pluripotent cells that are immunopositive for both the neural progenitor marker nestin and a pluripotent cell marker are provided. The cells exhibit rapid doubling times and can be maintained in vitro for extended periods. Also provided are cell cultures containing the pluripotent cells, a method of transplanting human pluripotent cells to a host, and a method of reducing seizure activity in a subject. These pluripotent cells, when transplanted into the ventricle of a host animal, migrate to the site of damage and adopt a suitably corrective phenotype, resulting in both structural and functional restoration.Type: GrantFiled: July 20, 2009Date of Patent: February 5, 2013Assignee: Celavie Biosciences, LLCInventor: Oleg V. Kopyov
-
Patent number: 8337812Abstract: It is intended to provide an agent for regulating axon extension during neuranagenesis by regulating ephrin-Eph receptor signaling mechanisms and to provide a mouse having abnormal ephrin-Eph receptor signaling mechanisms. The present invention relates to a regulator of axon extension, comprising an agent for promoting or suppressing the function of ?-chimerin, and to a miffy (mfy) mouse derived from a B6 strain, which displays autosomal recessive inheritance of an abnormal walking trait exhibiting a hopping gait with left-right synchronized movement of limbs and has mutation in an ?-chimerin gene.Type: GrantFiled: August 21, 2008Date of Patent: December 25, 2012Assignee: RIKENInventors: Takuji Iwasato, Shigeyoshi Itohara, Ryosuke Takahashi, Haruhisa Inoue
-
Patent number: 8338175Abstract: The present disclosure describes a tissue system with conjunctival cells, including conjunctival stem cells. The conjunctival tissue system is derived from isolated tissue comprising conjunctival cells, and is suitable for restoring ocular surface impairments, particularly those that result from damaged or diseased conjunctiva. The tissue system is generated using a simple single medium culture scheme, and a support material, such as human amniotic membrane. The conjunctival tissue system generate is suitable for transplantation to treat the ocular surface of an eye of a subject that is damaged or diseased.Type: GrantFiled: February 23, 2007Date of Patent: December 25, 2012Assignee: Reliance Life Sciences Pvt. Ltd.Inventors: Kashyap Subhadra Devi, Kishore Reddy, Viraf Vasania
-
Patent number: 8337833Abstract: Methods of causing an improvement in central nervous system function are provided. The methods include administering an aliquot of stem cells to the patient, the cells being derived from blood, e.g., umbilical cord blood. In some cases a growth factor is administered with the cells.Type: GrantFiled: May 11, 2010Date of Patent: December 25, 2012Assignees: The General Hospital Corp., ViaCord, LLCInventors: Morey Kraus, Seth Finklestein, Paul Clark
-
Patent number: 8309352Abstract: The present invention relates to the use of umbilical cord blood cells from a donor or patient to provide neural cells which may be used in transplantation. The isolated cells according to the present invention may be used to effect autologous and allogeneic transplantation and repair of neural tissue, in particular, tissue of the brain and spinal cord and to treat neurodegenerative diseases of the brain and spinal cord.Type: GrantFiled: November 9, 2006Date of Patent: November 13, 2012Assignee: University of South FloridaInventors: Paul Sanberg, Juan Sanchez-Ramos, Alison Willing, Daniel D. Richard
-
Patent number: 8304237Abstract: The invention relates to a method for cultivating biologic cells (1), wherein cells (1) are grown on a substrate (10) having a plurality of substrate openings (11), and wherein cell aggregates (2) are formed, including groups of cells (1) that span the substrate openings (11). A separation of the cell aggregates (2) from the substrate (10) by extracting the cell aggregates (2) from the substrate openings (11) can be provided. The invention further relates to a cell-cultivating device (100), including a substrate (10) having a plurality of substrate openings (11) and cell aggregates (2) including groups of cells (1) that span the substrate openings (11). The cell aggregates (2) are particularly used in high throughput tests with biologically active substances or in methods of tissue cultivation.Type: GrantFiled: June 13, 2008Date of Patent: November 6, 2012Assignee: Fraunhofer-Gesellschaft zur Foerderung der Angewandten Forschung e.V.Inventors: Charli Kruse, Sandra Danner
-
Patent number: 8263822Abstract: Disclosed are a composition for inhibiting the expression of GA733-2 or for detecting GA733-2, which comprises TREM-2 gene or protein, a transgenic animal containing same, and a method using the same.Type: GrantFiled: February 18, 2009Date of Patent: September 11, 2012Assignee: GLO BiotechInventors: Hyung-Sik Kang, Eun-Mi Kim, Dong-Hern Kim, Ha-Rim Choi, Eun-Hee Lee, Il-Soo Kim, Chang-Eon Park
-
Patent number: 8252586Abstract: This invention provides a system for efficiently producing differentiated cells from pluripotent cells, such as human embryonic stem cells. Rather than permitting the cells to form embryoid bodies according to established techniques, differentiation is effected directly in monolayer culture on a suitable solid surface. The cells are either plated directly onto a differentiation-promoting surface, or grown initially on the solid surface in the absence of feeder cells and then exchanged into a medium that assists in the differentiation process. The solid surface and the culture medium can be chosen to direct differentiation down a particular pathway, generating a cell population that is remarkably uniform. The methodology is well adapted to bulk production of committed precursor and terminally differentiated cells for use in drug screening or regenerative medicine.Type: GrantFiled: June 3, 2009Date of Patent: August 28, 2012Assignee: Geron CorporationInventors: Melissa K. Carpenter, R. Scott Thies
-
Patent number: 8252585Abstract: This invention provides populations of neural progenitor cells, differentiated neurons, glial cells, and astrocytes. The populations are obtained by culturing stem cell populations (such as embryonic stem cells) in a cocktail of growth conditions that initiates differentiation, and establishes the neural progenitor population. The progenitors can be further differentiated in culture into a variety of different neural phenotypes, including dopaminergic neurons. The differentiated cell populations or the neural progenitors can be generated in large quantities for use in drug screening and the treatment of neurological disorders.Type: GrantFiled: December 11, 2008Date of Patent: August 28, 2012Assignee: Geron CorporationInventor: Melissa K. Carpenter
-
Patent number: 8247385Abstract: Provided herein are compositions and methods for treating and/or preventing neurodegenerative disease, such as Alzheimer's disease. In particular aspects, compositions administered herein encode a cellular immune response element. The compositions may be prepared and administered in such a manner that the cellular immune response element coding sequence is expressed in the subject to which the composition is administered. The compositions include expression systems, delivery systems, and certain cellular immune response element genes.Type: GrantFiled: February 4, 2008Date of Patent: August 21, 2012Inventor: Tai June Yoo
-
Patent number: 8236563Abstract: The present invention provides a method of differentiating progenitor cells to produce a population containing protected neuronal cells. A method of the invention includes the steps of contacting the progenitor cells with a differentiating agent; and introducing into the progenitor cells a nucleic acid molecule encoding a MEF2 polypeptide or an active fragment thereof, thereby differentiating the progenitor cells to produce a population containing protected neuronal cells. In one embodiment, the MEF2 polypeptide is human MEF2C or an active fragment thereof.Type: GrantFiled: March 31, 2011Date of Patent: August 7, 2012Assignee: Sanford-Burnham Medical Research InstituteInventors: Stuart A Lipton, Shu-ichi Okamoto
-
Patent number: 8232100Abstract: Disclosed are embryonic stem cell-derived dendritic cells, genetically modified immature dendritic cells capable of maturation, as well as methods for the production of such cells. In one embodiment, the cells made be produced by a method comprising the steps of providing a population of embryonic stem cells; culturing the embryonic stem cells in the presence of a cytokine or combination of cytokines which brings about differentiation of the embryonic stem cells into dendritic cells; and recovering the dendritic cells from the culture. In a further embodiment, the cells may be genetically modified.Type: GrantFiled: July 21, 2010Date of Patent: July 31, 2012Assignee: Isis Innovation LimitedInventors: Herman Waldmann, Paul J. Fairchild, Richard Gardner, Frances Brook
-
Patent number: 8227246Abstract: This invention provides an isolated disc stem cell population, compositions, and methods of obtaining and growing the same. Moreover, this invention provides an isolated discosphere, compositions, and methods of obtaining and growing the same. An artificial disc containing the cells of the present invention is provided together with methods of making the same. This invention also provides a method of treating a subject having a herniated disc utilizing the cells and methods of the invention.Type: GrantFiled: July 7, 2008Date of Patent: July 24, 2012Assignee: DiscgenicsInventors: Valery Kukekeov, Christopher Duntsch, Tatyana Igantova
-
Patent number: 8206699Abstract: One form of the present invention is directed to a method of remyelinating demyelinated axons by treating the demyelinated axons with oligodendrocyte progenitor cells under conditions which permit remyelination of the axons. Another aspect of the present invention relates to a method of treating a subject having a condition mediated by a loss of myelin or a loss of oligodendrocytes by administering to the subject oligodendrocyte progenitor cells under conditions effective to treat the condition mediated by a loss of myelin or a loss of oligodendrocytes. A further aspect of the present invention relates to an in vitro method of identifying and separating oligodendrocyte progenitor cells from a mixed population containing other mammalian brain or spinal cord cell types. This further aspect of the present invention involves removing neurons and neuronal progenitor cells from the mixed population to produce a treated mixed population.Type: GrantFiled: April 29, 2008Date of Patent: June 26, 2012Assignee: Cornell Research Foundation, Inc.Inventors: Steven A. Goldman, Neeta Singh Roy, Martha Windrem
-
Patent number: 8187586Abstract: Methods of inducing apoptosis in hyperproliferative cells, particularly cancer cells are provided. Such method involves increasing the levels of a potassium channel modulatory protein in the cell. Examples of such proteins are native KChAP protein, a biologically active variant of native KChAP protein, or a biologically active KChAP-related protein (collectively referred to hereinafter as “KChAP protein”). In one embodiment, the cells are contacted with the KChAP protein under conditions permitting uptake of the protein by the cells. In another embodiment, the cells are contacted with (i) a nucleic acid encoding the KChAP protein, and (ii) a promoter active in the cancer cell, wherein the promoter is operably linked to the region encoding the KChAP protein, under conditions permitting the uptake of the nucleic acid by the cancer cell. Methods of detecting cancerous cells in a biological sample selected from the group consisting of a colorectal tissue sample or brain tissue sample are also provided.Type: GrantFiled: February 23, 2004Date of Patent: May 29, 2012Assignee: Case Western Reserve UniversityInventors: Arthur M. Brown, Barbara A. Wible